Uptake of Autologous and Allogenic Tumor Cell Antigens by Dendritic Cells

uptake of autologous and allogenic tumor cell antigens by dendritic cells

background: dendritic cells (dcs) are professional antigen presenting cells (apcs), and there is considerable interest in their application as a cellular adjuvant for cancer immunotherapy.  previous studies indirectly demonstrated that dcs were able to take up tumor lysate (crude soluble tumor antigens) and also cross-present tumor associated antigens (taa) which elicits anti-tumor immune respo...

Antigens by Activated Dendritic Cells Cells and Presentation of Released Tumor Peroxynitrite-Dependent Killing of Cancer

Peroxynitrite-dependent killing of cancer cells and presentation of released tumor antigens by activated dendritic cells.

Dendritic cells (DCs), essential for the initiation and regulation of adaptive immune responses, have been used as anticancer vaccines. DCs may also directly trigger tumor cell death. In the current study, we have investigated the tumoricidal and immunostimulatory activities of mouse bone marrow-derived DCs. Our results indicate that these cells acquire killing capabilities toward tumor cells o...

Acidosis improves uptake of antigens and MHC class I-restricted presentation by dendritic cells.

It is widely appreciated that inflammatory responses in peripheral tissues are usually associated to the development of acidic microenvironments. Despite this, there are few studies aimed to analyze the effect of extracellular pH on immune cell functions. We analyzed the impact of acidosis on the behavior of dendritic cells (DCs) derived from murine bone marrow. We found that extracellular acid...

Tumor-infiltrating dendritic cells exhibit defective cross-presentation of tumor antigens, but is reversed by chemotherapy.

Cross-presentation defines the unique capacity of an APC to present exogenous Ag via MHC class I molecules to CD8(+) T cells. DCs are specialized cross-presenting cells and as such have a critical role in antitumor immunity. DCs are routinely found within the tumor microenvironment, but their capacity for endogenous or therapeutically enhanced cross-presentation is not well characterized. In th...

Presentation of renal tumor antigens by human dendritic cells activates tumor-infiltrating lymphocytes against autologous tumor: implications for live kidney cancer vaccines.

The clinical impact of dendritic cells (DCs) in the treatment of human cancer depends on their unique role as the most potent antigen-presenting cells that are capable of priming an antitumor T-cell response. Here, we demonstrate that functional DCs can be generated from peripheral blood of patients with metastatic renal cell carcinoma (RCC) by culture of monocytes/macrophages (CD14+) in autolo...